European Commission approves Rhokiinsa to reduce elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.-Aerie Pharma
Aerie Pharmaceuticals, Inc. announced the European Commission (EC) has granted a marketing authorisation for Rhokiinsa (netarsudil ophthalmic solution) 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.
The marketing authorisation application (MAA) for Rhokiinsa was accepted for review by the European Medicines Agency (EMA) in October 2018. Aerie received a positive scientific opinion recommending approval of the Rhokiinsa MAA from the EMA�s Committee for Medicinal Products for Human Use (CHMP) in September 2019.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.